Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Pharmacogenomic profile of a central European urban random population-Czech population

Proietti, R, Maranho Neto, GA, Kunzova, S, Re, OL, Ahola-Olli, A, Heliste, J, Gonzalez-Rivas, JP and Vinciguerra, M (2023) Pharmacogenomic profile of a central European urban random population-Czech population. PLoS ONE, 18 (4). ISSN 1932-6203

Pharmacogenomic profile of a central European urban random population-Czech population.pdf - Published Version
Available under License Creative Commons Attribution.

Download (721kB) | Preview


The genetic basis of variability in drug response is at the core of pharmacogenomics (PGx) studies, aiming at reducing adverse drug reaction (ADR), which have interethnic variability. This study used the Kardiovize Brno 2030 random urban Czech sample population to analyze polymorphisms in a wide spectrum of genes coding for liver enzymes involved in drug metabolism. We aimed at correlating real life drug consumption with pharmacogenomic profile, and at comparing these data with the SUPER-Finland Finnish PGx database. A total of 250 individuals representative of the Kardiovize Brno 2030 cohort were included in an observational study. Blood DNA was extracted and 59 single nucleotide polymorphisms within 13 genes (BCHE, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A5, F2, F5, IFNL3, SLCO1B1, TPMT, UGT1A1, VKORC1), associated to different drug metabolizing rates, were characterized by genotyping using a genome wide commercial array. Widely used drugs such as anti-coagulant warfarin and lipid lowering agent atorvastatin were associated to an alarmingly high percentage of users with intermediate/poor metabolism for them. Significant differences in the frequency of normal/intermediate/poor/ultrarapid/rapid metabolizers were observed for CYPD26 (p<0.001), CYP2C19 (p<0.001) and UGT1A1 (p<0.001) between the Czech and the Finnish study populations. Our study demonstrated that administration of some popular drugs to a Czech random sample population is associated with different drug metabolizing rates and therefore exposing to risk for ADRs. We also highlight interethnic differentiation of some common pharmacogenetics variants between Central (Czech) and North European (Finnish) population studies, suggesting the utility of PGx-informed prescription based on variant genotyping.

Item Type: Article
Uncontrolled Keywords: Humans; Cytochrome P-450 CYP2D6; Pharmacogenetics; Genotype; Polymorphism, Genetic; Czech Republic; Vitamin K Epoxide Reductases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2C19; Liver-Specific Organic Anion Transporter 1; Humans; Pharmacogenetics; Cytochrome P-450 CYP2C19; Czech Republic; Genotype; Polymorphism, Genetic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2C9; Liver-Specific Organic Anion Transporter 1; Vitamin K Epoxide Reductases; General Science & Technology
Subjects: R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
Divisions: Nursing & Allied Health
Publisher: Public Library of Science (PLoS)
SWORD Depositor: A Symplectic
Date Deposited: 19 Jul 2023 08:23
Last Modified: 19 Jul 2023 08:30
DOI or ID number: 10.1371/journal.pone.0284386
Editors: Al-Eitan, L
URI: https://researchonline.ljmu.ac.uk/id/eprint/20430
View Item View Item